Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial

Hiten D. Patel, Farzana A. Faisal, Bruce J. Trock, Gregory A. Joice, Zeyad R. Schwen, Phillip M. Pierorazio, Michael H. Johnson, Trinity J. Bivalacqua, Misop Han, Michael A. Gorin, H. Ballentine Carter, Alan W. Partin, Christian P. Pavlovich, Mohamad E. Allaf

Research output: Contribution to journalArticlepeer-review

Abstract

In the Prevention of Venous Thromboembolism Following Radical Prostatectomy (PREVENTER) randomized trial, pharmacologic prophylaxis did not reduce the rate of symptomatic (relative risk [RR] 0.40 [95% confidence interval {CI} 0.08–2.03], p = 0.267) or overall (RR 0.97 [95% CI 0.25–3.81], p = 0.967) venous thromboembolism significantly. There was no increase in adverse events including symptomatic lymphoceles or bleeding.

Original languageEnglish (US)
Pages (from-to)360-368
Number of pages9
JournalEuropean Urology
Volume78
Issue number3
DOIs
StatePublished - Sep 2020

Keywords

  • Clinical trial
  • Evidence-based medicine
  • Quality improvement
  • Radical prostatectomy
  • Surgery
  • Venous thromboembolism

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial'. Together they form a unique fingerprint.

Cite this